Showing results (71-80 of 78) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
European Journal of Haematology. Supplementum|August 7, 2001
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacyS J Proctor, P R Taylor, B Angus, et al.Leukemia & Lymphoma|October 24, 2000
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacyG H Jackson, B Angus, P J Carey, et al.Leukemia|August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialK D Boyd, F M Ross, L Chiecchio, et al.Blood Cancer Journal|April 1, 2017
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle controlC Pawlyn, M D Bright, A F Buros, et al.Journal of Medical Genetics|October 26, 2007
Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphomaL J Worrillow, A G Smith, K Scott, et al.Leukemia|December 17, 2015
Genetic factors influencing the risk of multiple myeloma bone diseaseD C Johnson, N Weinhold, J Mitchell, et al.Blood Cancer Journal|December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trialJ R Jones, D A Cairns, W M Gregory, et al.Leukemia|June 7, 2017
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patientsV Shah, A L Sherborne, B A Walker, et al.Pageof 8